Summary. Bordetella pertussis produces several potential virulence factors. One of these is an adenylate cyclase which penetrates eukaryotic cells, is activated by calmodulin and generates high levels of intracellular CAMP. We have found that pertussis infection in man leads to production of high titres (2000-8000) of anti-B. pertussis adenylate cyclase antibodies. Such antibodies also are produced after pertussis vaccination. They persist into adulthood, cross the placenta and disappear a few months after birth. The anti-adenylate cyclase antibodies found in human serum during pertussis infection do not activities of the enzyme.
Introduction
Bordetellapertussis, the causative agent of whooping cough, produces several potential virulence factors that may play a role in the pathogenesis of the disease. '* The most studied and best characterised virulence factor is pertussis toxin (PT). PT causes many biological responses including lymphocytosis, histamine sensitisation and stimulation of insulin secretion," This toxin has recently been purified and shown to ADP-ribosylate several guanine-nucleotide binding protein^.^ ADP-ribosylation of Gi , the inhibitory guanine-nucleotide binding protein of the hormone-sensitive host adenylate cyclase (AC) system, blocks receptormediated inhibition of AC, thereby leading to increased intracellular cAMP level^.^ A role for PT in immunity to B. pertussis infection has been demonstrated both in animal models and in human disease. In mice, passive or active immunisation with PT induces protection from the disease produced by both intracerebral and aerosol challenge~.~. Granstrom et a1.6 demonstrated a rise in neutralising antibodies to PT in human sera after infection.
neutralise the catalytic and penetrative Another toxin that dramatically affects host cAMP metabolism is B. pertussis AC. The location of the enzyme in the bacterial cell is mainly extracytoplasmic7* and its activity strongly depends on the eukaryotic calcium-binding protein calmodulin (CaM).9 The enzyme penetrates eukaryotic cells and, upon activation by CaM, produces high levels of intracellular CAMP. lo* l 1 As a result, bactericidal functions of polymorphonuclear leucocytes and macrophages are impaired.'. l o Thus, the enzyme may play an important role in the pathogenesis of the disease by inhibiting host defences. Weiss et al. showed, by transposon Tn5-induced mutagenesis, that a B. pertussis strain deficient in AC was avirulent in an animal model of pertussis infection. Moreover, virulence for mice was restored when the mutant harboured a recombinant plasmid expressing AC activity. Recently, B. pertussis AC was purified, cloned and the genetic determinant sequenced. l 3 -I 6 The availability of a purified preparation of B. pertussis AC has enabled us to test for the presence of anti-AC antibodies in patients with pertussis and in subjects after vaccination.
Materials and methods

Patients and subjects
Fifteen patients aged 6-61 (mean 23 SD 18) years with pertussis were included in the study. Although pertussis is mainly considered to be a disease of the very young, it has recently been observed more frequently in older children and adults." Two of the patients had not been vaccinated and in four patients the vaccination status was unknown. Serum was obtained by two of us (E.W. and R.K.) 15-100 (mean 37 SD 21) days after symptoms started. Diagnosis of pertussis in suspected cases was based on a high titre of IgG against PT. ' Additionally all these subjects had a high titre of IgA antibodies against a whole-cell lysate of B. pertussis in comparison with a standard reference serum.lg These patients also showed PT-neutralising antibodies as determined by the Chinese hamster ovary (CHO) neutralisation test.6 Serum samples were also obtained from four neonates (cord blood), four unvaccinated infants 4-5 months old, four vaccinated children 2-3 years old, and four vaccinated adults 25-40 years old. IgG against PT and PTneutralising antibodies (CHO assay) were determined. The relevant patients and other subjects, including mothersof neonates, had been vaccinated with the wholecell vaccine in childhood. The four vaccinated children were immunised three times during their first year of life, and given a booster-dose a year later. None of the control subjects had had clinical pertussis.
Purijication of B. pertussis AC
Purified preparations of B. pertussis AC were obtained from a wild type B. pertussis strain and from a cloned Escherichia coli strain expressing the enzyme. B. pertussis strain 165 was grown and harvested as described previously." The 200-Kda form of the enzyme was purified according to the procedure of Rogel et al. This form of the enzyme was chosen because it represents the product of the entire B. pertussis AC gene. 16-2o A gene library of B. pertussis was constructed from chromosomal DNA of strain Tab1 by Brownlie et al.' A 10-kb DNA fragment, containing the structural gene of B. pertussis AC and two out of three genes required for AC secretion,21 was subcloned into the vector pIC20H to give the plasmid pRMB3. This plasmid was transformed into E. coli H1469 Loii strain and the enzyme produced was purified as described previously.
Immuno blo t t ing
Purified 200-Kda form of the enzyme at a concentration of 0.5-1 pg/lane was subjected to polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulphate (SDS-PAGE) and then electrophoretically transferred to nitrocellulose in a buffer containing 15.6 mM Tris-HCl and 120 mM glycine at pH 8.3. The transfer was conducted for 2 h at 190 mA. The nitrocellulose was cut into individual strips, blocked for 30 min with phosphatebuffered saline (PBS) containing bovine serum albumin (BSA) 2% w/v and then incubated overnight at 4°C with dilutions of various sera, in a final volume of 10 ml. The incubation solution contained PBS supplemented with BSA 2% w/v. The strips were then washed four times, each for 10 min, with the following solutions : (1) PBS, (2 and 3) PBS containing Tween 20 0.2% w/v, and (4) PBS. The nitrocellulose strips were then incubated for 2 h at room temperature in PBS containing BSA 2% w/v which was supplemented with 251-labelled protein A 105cpm/ ml. Unbound protein A was removed by repeated washing with PBS containing Tween 20 0.2% w/v. The strips were dried and autoradiographed at -70°C for 14 h.
Inhibition of AC activity
AC activity was determined in a total volume of 50 pl as described previously. ' ' The ability of the various sera to inhibit AC activity was assessed as follows: 2 0 4 volumes of undiluted sera, and of sera diluted 1 in 10 and 1 in 100 in PBS supplemented with BSA 1% w/v, were incubated for 4 h at 4°C with 20 p1 of the 200-Kda form of the enzyme purified from B. pertussis, at an activity of 8 nmol of cAMP/min/ml. At the end of the incubation period, three samples, each of 10 pl, were withdrawn and assayed for AC activity. As a control we used neutralising anti-B. pertussis AC serum. ' This serum was obtained from only one guinea-pig out of six immunised with purified B. pertussis AC ; the rest of the animals produced non-neutralising anti-B. pertussis AC antibodies (E. Hanski, unpublished observation). This neutralising serum completely inhibited the AC activity of the 200-Kda form of the enzyme at dilutions up to 1 in 200.
Inhibition of penetrative activity
Penetrative activity was determined by measurement of intracellular CAMP accumulation as described previously. ' Human lymphocytes were used as target cells for the enzyme. The invasive form of B. pertussis AC was isolated by gel filtration of a crude bacterial extract.15 The specific activity of this preparation was 3.1 pmol of cAMP/min/mg protein and its capacity for penetration was 0.35pmol of cAMP/mg of lymphocyte protein/mg of bacterial protein. The invasive enzyme (40 pl) was incubated with the various sera (40 pl of undiluted serum or serum diluted 1 in 10 or 1 in 100 in PBS supplemented with BSA 0.1% w/v) for 5 h at 4°C before testing. Then, three 20-pl samples were withdrawn and the penetrative activity was determined. In control experiments the neutralising anti-B. pertussis AC serum completely blocked the entry of the invasive form of enzyme at dilutions of up to 1 in 200.
Results
We tested human sera for the presence of anti-B. pertussis AC antibodies. High amounts of anti-AC antibodies were detected in all patients with pertussis (table I). In contrast, anti-AC antibodies could not be detected in sera from healthy nonvaccinated infants as shown for one of them in fig.  1 . The patients' sera used in this study contained IgA antibodies against a whole-cell lysate of B . king titres were even higher, approaching those detected during pertussis infection. Table I shows the titres of anti-B. pertussis AC antibodies in the various groups studied. Very high titres (2000-8000) were found in patients with pertussis, irrespective of their vaccination status. In contrast, in non-vaccinated infants 4-5 months old, no such antibodies could be detected even at a dilution of 1 in 20 (table I; fig. 1 ). However, anti-B. pertussis AC antibodies could be detected in cord blood and in vaccinated children and adults.
To exclude the possibility that a minor contaminant of the AC preparation, of similar molecular weight, was responsible for the interactions on the Western blots, the control experiment shown in fig.  2 was performed. B. pertussis AC was purified from an E. coli strain harbouring a plasmid that encodes for the structural gene of B. pertussis AC. ' 39 *' All patients' sera interacted with the enzyme produced in E. coli, as shown for one patient in fig. 2 . This interaction was specific since recognition of the enzyme was not detected with serum from a nonvaccinated infant.
The ability of sera from pertussis patients to neutralise B. pertussis AC activity was examined by two assays: inhibition of enzymic activity and inhibition of penetration of the enzyme into target cells. None of the human sera examined showed such properties. In animals (rabbits and guineapigs) immunised with purified B. pertussis AC, high titres of anti-B. pertussis AC were detected by immunoblotting. 14, ' However, neutralisation of enzymic activity and penetrative ability of B. pertussis AC was found in the serum of only one guinea-pig out of six immunised. This serum completely inhibited both activities at a dilution of 1 in 2O0.l5
Discussion
This study demonstrates the capacity for production of antibodies against B. pertussis AC in man and is the first direct evidence that AC is produced by B. pertussis during infection. The anti-AC antibodies are produced in high titres after infection. These antibodies are also produced after vaccination, persist into adulthood, cross the placenta and disappear a few months after birth. It appears that higher titres of anti-AC antibodies are produced after infection than after vaccination, although this may be due to differences in the timing of the observations. Further studies are required to substantiate this finding. Recently, it has been reported that anti-filamentous haemagglutinin (FHA) antibodies appear in sera of pertussis Z. FARFEL ET AL. reported that hyperimmune human sera could neutralise B. pertussis AC activity but details were not provided. The apparent discrepancy between these results and ours is as yet not understood. In the case of PT, the appearance of neutralising antibodies has been considered to be further evidence for its role in virulence. Granstrom et a1. 6 claimed that PT-neutralising antibodies are important for long term immunity against pertussis. However, some of the patients reported in their study, in spite of having initial high titres of PTneutralising antibodies, developed pertussis. Furthermore, Trollfors et aZ.28 did not find a correlation between anti-PT IgG and CHO-neutralising antibodies during pertussis infection. In some of their patients, CHO-neutralising antibodies were not detected. However, it was not reported whether or not the course of the disease in these patients was more severe than in the other patients.
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